Cantor Fitzgerald Predicts Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Prothena in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biotechnology company will post earnings per share of ($3.97) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share.

Several other equities research analysts also recently commented on the company. Bank of America decreased their price objective on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. Chardan Capital initiated coverage on shares of Prothena in a research note on Friday, December 20th. They issued a “buy” rating and a $40.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $48.00 target price (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Finally, StockNews.com cut shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.50.

Prothena Price Performance

Shares of PRTA opened at $14.43 on Wednesday. The stock has a 50-day moving average of $14.29 and a 200-day moving average of $18.02. Prothena has a one year low of $11.70 and a one year high of $34.65. The company has a market cap of $776.48 million, a PE ratio of -5.82 and a beta of 0.10.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.08. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm’s revenue was down 98.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.38 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PRTA. Orion Portfolio Solutions LLC grew its position in Prothena by 4.4% during the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock valued at $293,000 after buying an additional 739 shares during the period. Pinnacle Associates Ltd. grew its stake in Prothena by 2.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company’s stock valued at $2,104,000 after buying an additional 2,847 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock worth $1,440,000 after purchasing an additional 3,163 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 4,026 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its holdings in shares of Prothena by 30.4% in the second quarter. Ensign Peak Advisors Inc now owns 21,643 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 5,050 shares during the period. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.